In a patient with chronic lymphocytic leukemia who develops a new soft‑tissue mass, how should it be evaluated and managed?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 24, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Evaluation and Management of Soft Tissue Mass in CLL

A new soft tissue mass in a patient with chronic lymphocytic leukemia should be biopsied to rule out Richter transformation to diffuse large B-cell lymphoma (DLBCL), which occurs in 2-15% of CLL patients and carries a poor prognosis requiring immediate treatment modification.

Diagnostic Approach

Imaging to Guide Biopsy

PET-CT scan is the preferred imaging modality to identify the optimal biopsy site and assess for transformation 1, 2. Key imaging features include:

  • SUVmax ≥10 suggests Richter transformation in patients not on kinase inhibitor therapy 2
  • However, PET alone lacks sufficient sensitivity/specificity in patients on ibrutinib 2
  • Direct biopsy to the lesion with highest FDG uptake 2

Tissue Diagnosis is Mandatory

Excisional lymph node biopsy is required for definitive diagnosis 2. The hierarchy of biopsy approaches:

  1. Excisional biopsy (preferred if accessible)
  2. Incisional biopsy (second choice)
  3. Core needle biopsy (acceptable when surgical biopsy not feasible) 2

Critical caveat: PET imaging alone is insufficient for diagnosis—tissue confirmation is mandatory 2.

Essential Pathologic Analysis

Once tissue is obtained, determine clonal relationship between the DLBCL and underlying CLL by comparing IGHV sequences 1. This distinction is crucial because:

  • Clonally related DLBCL (Richter transformation): Poor prognosis, requires aggressive therapy and consideration of allogeneic stem cell transplant
  • Clonally unrelated DLBCL: Treat as de novo DLBCL with standard R-CHOP, better prognosis 1

Management Based on Findings

If Richter Transformation Confirmed (Clonally Related)

Enrollment in a clinical trial is the preferred initial treatment option 2. Outside of trials:

First-line therapy options (all have limited efficacy):

  • R-CHOP: 67% ORR, median OS 21 months 2
  • R-EPOCH: 39% ORR, median OS 6 months 2
  • Modified R-hyperCVAD: 43% ORR but significant toxicity 2

Prognostic factors for better response: Elevated platelet counts, higher hemoglobin, lower beta-2-microglobulin, lower LDH 2

Definitive management: Allogeneic stem cell transplant should be recommended to all patients with clonally-related Richter transformation who have an available donor and sufficient fitness 1. This is the only potentially curative approach given the typically short response duration to chemotherapy.

If Clonally Unrelated DLBCL

Manage as de novo DLBCL per standard lymphoma guidelines (R-CHOP first-line, reserving stem cell transplant for non-responders or relapse) 1.

If No Transformation (CLL Infiltrate Only)

If biopsy shows only CLL infiltration without transformation, treatment depends on whether the patient meets criteria for active disease requiring therapy 1:

  • Massive/progressive/symptomatic lymphadenopathy (>10 cm)
  • Progressive marrow failure
  • Constitutional symptoms

If no active disease criteria met, continue observation 1.

Important Pitfalls to Avoid

  1. Do not rely on PET SUV values alone—tissue diagnosis is essential 2
  2. Do not assume all soft tissue masses are benign CLL infiltrates—transformation risk is 2-15% and increases with prior chemoimmunotherapy exposure 1
  3. Do not skip clonal relationship testing—this fundamentally changes prognosis and treatment approach 1
  4. Do not delay consideration of allogeneic transplant in fit patients with clonally-related disease, as response duration to chemotherapy is typically short 1

References

2
Guideline

nccn guidelines insights: chronic lymphocytic leukemia/small lymphocytic lymphoma, version 2.2019.

Journal of the National Comprehensive Cancer Network : JNCCN, 2019

Related Questions

What criteria are used to start treatment in a patient with chronic lymphocytic leukemia?
What is the appropriate management for a patient with Rai stage 0 chronic lymphocytic leukemia whose white blood cell count increased from a baseline of 24 ×10^9/L to 85 ×10^9/L and then 91 ×10^9/L with an absolute lymphocyte count of 84 ×10^9/L?
Can chronic lymphocytic leukemia (CLL) achieve remission?
In a patient with chronic lymphocytic leukemia and a white blood cell count of 374 × 10⁹/L presenting to the emergency department, what are the emergent differential diagnoses and what immediate management steps should be taken?
Which vaccinations are indicated for a 48-year-old man with newly diagnosed chronic lymphocytic leukemia who is already up-to-date on annual influenza vaccine, COVID‑19 boosters, and a recent tetanus‑pertussis booster?
What are the recommended evaluation, treatment options, and follow‑up for a patient with a giant congenital nevus?
In a patient with visible (frank) hematuria, should I order a urine tumor antigen test (urotac)?
Should low‑dose aspirin (81 mg daily) be held in a patient with a subacute subdural hematoma?
How should I manage a 3-year-old with persistent low‑grade fever (100.5‑101.5 °F) and fatigue for two weeks while taking amoxicillin (Amoxil) for presumed pharyngitis?
How many drops of ciprofloxacin ophthalmic solution (Cipro‑Optic) should be used for otitis externa?
In an elderly woman with ADHD and dysthymia who refuses stimulant therapy because of difficulty obtaining it, should I start bupropion (Wellbutrin)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.